Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|GLPG0187||GLPG0187 is an integrin receptor antagonist, which may decrease angiogenesis and reduce tumor growth and metastasis (PMID: 25156971, PMID: 26792581).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||no benefit||GLPG0187||Phase I||Actionable||In a Phase I trial, continuous treatment with GLPG0187 demonstrated safety but lack of efficacy, with 15% (3/20) of patients demonstrating stable disease and no patients with tumor response (PMID: 26792581).||26792581|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|